Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Arcus Biosciences, Inc. (RCUS)

20.16   -0.1 (-0.49%) 05-31 12:18
Open: 20.17 Pre. Close: 20.26
High: 20.91 Low: 19.61
Volume: 354,048 Market Cap: 1,474(M)

Technical analysis

as of: 2023-05-31 11:49:24 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 26.29     One year: 30.7
Support: Support1: 19.04    Support2: 16.9
Resistance: Resistance1: 22.5    Resistance2: 26.29
Pivot: 18.84
Moving Average: MA(5): 19.57     MA(20): 18.89
MA(100): 18.87     MA(250): 23.33
MACD: MACD(12,26): 0.3     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 69.1     %D(3): 56.1
RSI: RSI(14): 55.6
52-week: High: 36.13  Low: 15.69
Average Vol(K): 3-Month: 1,013 (K)  10-Days: 1,205 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ RCUS ] has closed below upper band by 24.3%. Bollinger Bands are 16.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 22.4 - 22.53 22.53 - 22.63
Low: 19.88 - 20.05 20.05 - 20.18
Close: 20.02 - 20.26 20.26 - 20.46

Company Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Headline News

Tue, 30 May 2023
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual ... - Business Wire

Tue, 30 May 2023
Principal Financial Group Inc. Cuts Position in Arcus Biosciences ... - MarketBeat

Sat, 27 May 2023
Citigroup Maintains Arcus Biosciences (RCUS) Buy Recommendation - Nasdaq

Fri, 26 May 2023
Elevation, Arcus top healthcare gainers; Tilray, Monogram among ... - Seeking Alpha

Fri, 26 May 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace

Fri, 26 May 2023
Arcus Biosciences Inc (RCUS) has risen 21.37% Friday In Premarket Trading - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 73 (M)
Shares Float 49 (M)
% Held by Insiders 28.6 (%)
% Held by Institutions 75.6 (%)
Shares Short 7,810 (K)
Shares Short P.Month 7,680 (K)

Stock Financials

EPS -3.78
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.21
Profit Margin (%) -234.5
Operating Margin (%) -251.3
Return on Assets (ttm) -13.4
Return on Equity (ttm) -40
Qtrly Rev. Growth 38.9
Gross Profit (p.s.) -2.41
Sales Per Share 1.62
EBITDA (p.s.) -4
Qtrly Earnings Growth 0
Operating Cash Flow -314 (M)
Levered Free Cash Flow -119 (M)

Stock Valuations

PE Ratio -5.31
PEG Ratio 0
Price to Book value 2.44
Price to Sales 12.31
Price to Cash Flow -4.67

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.